Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ocular surface hydration enhancement refers to therapeutic interventions intended to maintain or restore adequate moisture on the ocular surface, primarily for the management of dry eye disease and related conditions. These approaches include the use of artificial tears, viscoelastic agents like hyaluronic acid, bioprotectants such as trehalose, and secretagogues like diquafosol sodium. Their common goals are to lubricate the ocular surface, improve tear film stability, reduce epithelial damage, and enhance patient comfort.
Lubrication of the ocular surface, Water retention in tear film, Stabilization and thickening of the mucoaqueous layer, Stimulation of tear secretion (for secretagogues), Protection against hyperosmolarity, Anti-inflammatory and epithelial healing
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ocular surface hydration enhancement.